Factsheet – Joint Clinical Assessment for Medicinal Products (January 2025)
The Regulation on Health Technology Assessment (Regulation (EU) 2021/2282) HTAR establishes a framework for conducting Joint Clinical Assessments (JCA) at EU level. These assessments support member states in their national Health Technology Assessment (HTA) processes, providing a scientific analysis of clinical evidence on the relative effects of a health technology (a medicinal product or a medical device) on health outcomes. This analysis can inform decisions on the allocation of budgetary resources in the field of health, including on pricing or reimbursement of health technologies.
Read the factsheet published by Directorate-General for Health and Food Safety on 10 January 2025.
OpenEdition vous propose de citer ce billet de la manière suivante :
lsgilbert (26 février 2025). Factsheet – Joint Clinical Assessment for Medicinal Products (January 2025). ELSIBI. Consulté le 25 avril 2025 à l’adresse https://doi.org/10.58079/13drw